Tesis de inversión · Activa
Radiopharmaceuticals cannot be stockpiled: the cancer isotope boom pays the networks, not the molecules
Every radioligand dose decays within days, so scale depends on licensed hot cells near patients, and that is where the profit pool quietly sits.
Publicada el 20 de agosto de 2026 · horizonte de 180 días · oferta y demanda
Este análisis aún no se ha traducido a este idioma, así que mostramos el original. La traducción llegará pronto.
Resultado de la cesta
-2,9%
pesos iguales, desde la publicación
El mercado en ese periodo
-0,4%
índice de referencia de la cesta
Ventaja sobre el mercado
-2,4%
en puntos porcentuales
Cadena causal: Radioligand therapy moves into earlier cancer lines → Medicare pays separately for costly PET tracers → Half-lives of days or hours make inventory impossible → Each therapy patient needs PET selection and follow-up → Growth needs licensed hot cells near the patient → Isotope supply and network density become the constraint → Isotope suppliers, accelerator makers, tracer networks
What this thesis rests on
Each one is a statement that has to be true. When a filing says otherwise, the thesis is in trouble, and this is where we say so.
-
○
Eckert & Ziegler's Medical segment revenue grows at least 10% year over year in each of the two quarterly reports published after this thesis.
financial · Unverified
-
○
Lantheus's radiodiagnostics revenue falls by no more than 10% year over year in each of the two quarterly reports published after this thesis.
financial · Unverified
-
○
CMS retains separate payment for diagnostic radiopharmaceuticals above the per day cost threshold in the CY2027 Hospital Outpatient Prospective Payment System rulemaking.
regulatory · Unverified
-
○
At least one new GMP radiopharmaceutical production site or hot cell expansion in the US or EU is announced by Eckert & Ziegler, Telix or Lantheus before 28 February 2027.
operational · Unverified
-
○
Telix keeps FDA marketing authorisation for Illuccix and discloses no supply interruption of its PSMA imaging products during the horizon.
competitive · Unverified
Assumptions are written in English, because that is the language of the filings we check them against.
Radioligand therapy has stopped being a niche of nuclear medicine and become a funded priority of the largest balance sheets in pharma. Novartis pushed Pluvicto into earlier lines of prostate cancer, and between 2023 and 2025 Eli Lilly, Bristol Myers Squibb, AstraZeneca and Novartis each bought a radiopharmaceutical developer outright. The pipeline that follows is not a handful of trials but dozens of programmes aimed at prostate, neuroendocrine, kidney and lung tumours, all of which converge on the same physical infrastructure.
Here is the part the market keeps mispricing. A radiopharmaceutical is the only drug class where inventory is physically impossible. Lutetium-177 loses half its activity in 6.6 days, actinium-225 in about 10 days, gallium-68 in 68 minutes and fluorine-18 in under two hours. There is no safety stock, no warehouse, no rebuilding of a supply buffer after a bad quarter. The dose is made to order for a named patient on a named day, and if the courier is late the product is simply weaker than the prescription. Every other pharmaceutical bottleneck in the last decade, from GLP-1 pens to sterile vials, could in principle be solved by running the line longer. This one cannot.
Abrir la tesis interactiva
Mapa causal interactivo, gráfico de la cesta frente al mercado y línea de tiempo completa de la tesis.
Abrir en Invesaro →
This is analysis, not investment advice and not a recommendation to buy or sell anything. We publish it and track it in public, mistakes included. Any decision is yours and yours alone.